Adjuvant therapy for colon cancer

Jeffrey Cilley, Mary F. Mulcahy*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Colon cancer is a leading cause of cancer and cancer deaths in Western countries. Although 5-fluorouracil is still the basis of adjuvant therapy, advances in drug development have led to increased efficacy with the addition of oxaliplatin and options for oral therapy with capecitabine. The benefit of adjuvant therapy for stage II disease is consistently small and not statistically significant. Future studies will evaluate the role of the biologic agents that have proved to be effective in metastatic disease and better delineate the population at risk by identifying prognostic and predictive markers.

Original languageEnglish (US)
Pages (from-to)161-166
Number of pages6
JournalCurrent oncology reports
Issue number3
StatePublished - May 2006

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Adjuvant therapy for colon cancer'. Together they form a unique fingerprint.

Cite this